| 5 star (2) | 100% |
pong (Chiang Mai) on 09/30/2026: 
The studies used a consistent recipe:
The case reports used even higher concentrations (40–70% supersaturated) with longer contact times. The DHAA (dehydroascorbic acid) serum reports describe lesions resolving in as little as 5–10 days.
One nuance worth respecting: DMSO drags everything through the skin, so the application site should be clean and free of other chemicals before use — that's not a "warning, " that's just how the solvent works.
The combination of pure vitamin C powder + DMSO has:
For slow-growing, superficial, non-melanoma lesions, this is one of the best-documented alternative approaches in existence. The data is sitting in plain sight in indexed journals.
pong (Chiang Mai) on 09/30/2026:
Normal skin cells survive because they hold higher catalase activity, an enzyme that neutralizes peroxide. Cancer cells, with their low catalase, get wrecked. This is why pharmacologic ascorbate kills tumors while sparing healthy tissue.
DMSO is the delivery vehicle. It temporarily disrupts the stratum corneum's lipid barrier and drags the ascorbate deep into the lesion — far faster than aqueous solutions, which historically needed 22+ weeks to show effect.
This is the one to know. A randomized controlled trial published in Biomedicine & Pharmacotherapy — not some preprint.
The setup: 25 patients, 29 biopsy-confirmed basal cell carcinomas. Half got 30% ascorbic acid in 95% DMSO applied twice daily for 8 weeks. Half got imiquimod (Aldara), the standard prescription cream.
The results:
| Outcome | Vitamin C + DMSO | Imiquimod |
|---|---|---|
| Lesion resolution (8 wks) | 86.7% | 57.1% |
| Hypopigmentation at 30-mo follow-up | 0% | 70% |
| Adverse effects | Fewer | More |
The ascorbate group beat the drug the dermatologist would have written you, with a p<0.05 result confirmed by punch biopsy. And zero scarring or pigment loss at follow-up, versus 70% of imiquimod patients left with white patches.
A newer preprint extended the same 30% ascorbic acid / 95% DMSO formulation to squamous cell carcinoma in situ (SCCIS) — 17 patients, 27 lesions, twice daily for 12 weeks.
Most of the "failures" actually downgraded from carcinoma to mere actinic keratosis — no longer cancer, just sun damage — and were mopped up with cryotherapy.
